Tuberculosis profile: Malaysia

Population 2022: 34 million

Estimates of TB burden*, 2022

	Number	(Rate per 100 000 population)
Total TB incidence	38 000 (31 000-44 000)	113 (92-130)
HIV-positive TB incidence	1 700 (1 400-2 000)	5 (4.2-6)
MDR/RR-TB incidence**	630 (490-760)	1.8 (1.4-2.3)
HIV-negative TB mortality	2 500 (1 600-3 600)	7.3 (4.7-10)
HIV-positive TB mortality	680 (440-970)	2 (1.3-2.9)

Estimated proportion of TB cases with MDR/RR-TB*, 2022

New cases	0.92% (0.8-1)
Previously treated cases	19% (14-24)

Universal health coverage and social protection*

č i		
TB treatment coverage (notified/estimated incidence), 2022	65% (56-80)	
TB patients facing catastrophic total costs		
TB case fatality ratio (estimated mortality/estimated incidence), 2022	8% (5-12)	
B case notifications, 2022		
Total new and relapse	24 79	
- % tested with rapid diagnostics at time of diagnosis	79	
- % with known HIV status	955	
- % pulmonary	86	
- % bacteriologically confirmed ^	719	
- % children aged 0-14 years	49	
- % women (aged ≥15 years)	335	
- % men (aged ≥15 years)	63'	
Total cases notified	25 39	

TB/HIV care in new and relapse TB patients, 2022

	Number	(%)
Patients with known HIV status who are HIV-positive	1 047	4.5%
- on antiretroviral therapy	346	33%

Drug-resistant TB care**, 2022

$\%$ of bacteriologically confirmed TB cases tested for rifampicin resistance - New cases ^	80%
$\%$ of bacteriologically confirmed TB cases tested for rifampicin resistance - Previously treated cases ^	64%
Laboratory-confirmed cases - MDR/RR-TB (without pre-XDR-TB/XDR-TB) ^^	153
Patients started on treatment - MDR/RR-TB (without pre-XDR-TB/XDR-TB) ***	123
Laboratory-confirmed cases - pre-XDR-TB or XDR-TB ^^	5
Patients started on treatment - pre-XDR-TB or XDR-TB ^^^	5
MDR/RR-TB cases tested for resistance to any fluoroquinolone	108

Treatment success rate and cohort size

	Success	Cohort
New and relapse cases registered in 2021	79%	20 710
Previously treated cases, excluding relapse, registered in 2021	59%	428
HIV-positive TB cases registered in 2021	56%	907
MDR/RR-TB cases started on second-line treatment in 2020	57%	155
Pre-XDR-TB/XDR-TB cases started on second-line treatment in 2020	50%	4

TB preventive treatment, 2022


% of HIV-positive people (newly enrolled in care) on preventive treatment	
% of household contacts of bacteriologically-confirmed TB cases on preventive treatment	14% (14-14)

Funding for TB

Funding for TB, 2022 (US\$ millions)	16
- % domestic funding	100%
- % international funding	0%
National TB budget, 2023 (US\$ millions)	17
- Funding source, domestic	100%
- Funding source, international	
Linfundad	0%


Incidence, New and relapse TB cases notified, HIV-positive TB incidence

(Rate per 100 000 population per year)




HIV-negative TB mortality

(Rate per 100 000 population per year)




Incidence, Notified cases by age group and sex, 2022


(Number)



Cases attributable to five risk factors, 2022 (Number)



Funding for TB (US\$ millions)



Generated 2023-12-16 by the World Health Organization (https://www.who.int/teams/global-tuberculosis-programme/data)

^{*} Estimates of TB burden are produced by WHO in consultation with countries. Ranges represent uncertainty intervals.
** RR is TB resistant to rifampicin (R); MDR is TB resistant to R + isoniazid; pre-XDR is TB resistant to R + any fluoroquinolone
^ Calculated for pulmonary cases only
^// Includes cases with unknown previous TB treatment history
^// Includes patients diagnosed before 2022 and patients who were not laboratory-confirmed